TY - JOUR
T1 - Predictive biomarkers for bevacizumab
T2 - Are we there yet?
AU - Maru, Dipen
AU - Venook, Alan P.
AU - Ellis, Lee M.
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Therapy targeting VEGF has become the standard of care in several solid malignancies. Early investigations attempting to identify predictive markers for the efficacy of therapy failed to identify any predictive markers that could help oncologists decide who should - and, more importantly, who should not - receive VEGF-targeted therapies. However, interest has been renewed in predictive biomarkers for VEGF-targeted therapies, especially in light of the fact that the U.S. Food and Drug Administration withdrew approval for use of bevacizumab, an antibody to VEGF, in patients with metastatic breast cancer. In a recent publication in the Journal of Clinical Oncology, investigators identified circulating VEGF and tumor neuropilin-1 expression as potential predictive biomarkers for bevacizumab. From this perspective, we provide a critical evaluation of the use of these markers and the need for validation in prospective clinical trials.
AB - Therapy targeting VEGF has become the standard of care in several solid malignancies. Early investigations attempting to identify predictive markers for the efficacy of therapy failed to identify any predictive markers that could help oncologists decide who should - and, more importantly, who should not - receive VEGF-targeted therapies. However, interest has been renewed in predictive biomarkers for VEGF-targeted therapies, especially in light of the fact that the U.S. Food and Drug Administration withdrew approval for use of bevacizumab, an antibody to VEGF, in patients with metastatic breast cancer. In a recent publication in the Journal of Clinical Oncology, investigators identified circulating VEGF and tumor neuropilin-1 expression as potential predictive biomarkers for bevacizumab. From this perspective, we provide a critical evaluation of the use of these markers and the need for validation in prospective clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=84878979173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878979173&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-3409
DO - 10.1158/1078-0432.CCR-12-3409
M3 - Review article
C2 - 23549876
AN - SCOPUS:84878979173
SN - 1078-0432
VL - 19
SP - 2824
EP - 2827
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 11
ER -